How India Exports Doxorubicin to the World

In the United States, doxorubicin is approved under multiple Abbreviated New Drug Applications (ANDAs), reflecting its established presence in the market. The FDA's Orange Book lists numerous approved ANDAs for doxorubicin, indicating a competitive landscape with multiple generic manufacturers. Notably, Sun Pharmaceutical Industries Limited, India's leading exporter of doxorubicin, has a significant market share in the U.S., highlighting the importance of FDA approvals for Indian exporters.

As of March 2026, there are no active FDA import alerts specifically targeting doxorubicin products from India. However, manufacturers must remain vigilant, as the FDA has issued import alerts for other pharmaceutical products due to quality concerns. For instance, Import Alert 66-66, updated in October 2024, addresses APIs that appear to be misbranded under section 502(f)(1) of the FD&C Act. Ensuring compliance with FDA regulations is crucial for maintaining uninterrupted access to the U.S. market.

In the European Union, doxorubicin is subject to stringent regulatory oversight by the European Medicines Agency (EMA). Several marketing authorization applications for doxorubicin products have been withdrawn or refused in recent years. For example, in July 2011, Sun Pharmaceutical Industries Europe B.V. withdrew its application for Doxorubicin SUN, intended for the treatment of metastatic breast cancer and other cancers. The withdrawal was due to the inability to address the Committee for Medicinal Products for Human Use's (CHMP) major objections within the available timeframe. Similarly, in May 2019, the CHMP adopted a negative opinion for Doxolipad, a doxorubicin product developed by TLC Biopharmaceuticals B.V., citing insufficient evidence of bioequivalence to the reference medicine. These instances underscore the rigorous evaluation processes in place within the EU.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) continues to align closely with EMA standards post-Brexit, ensuring that doxorubicin products meet comprehensive safety, efficacy, and quality requirements.

Doxorubicin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in cancer treatment worldwide. The WHO's inclusion of doxorubicin in its Essential Medicines List highlights the drug's importance in global health. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to ensure product quality and facilitate international trade.

In India, doxorubicin is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines, including doxorubicin. Manufacturers and exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for doxorubicin have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive environment has contributed to the widespread availability and affordability of doxorubicin globally.

In June 2025, the EMA's CHMP adopted a positive opinion recommending a new indication for Imbruvica in combination with doxorubicin for the treatment of adult patients with previously untreated mantle cell lymphoma eligible for autologous stem cell transplantation. This development reflects ongoing advancements in combination therapies involving doxorubicin.

In October 2024, the FDA updated Import Alert 66-66, addressing APIs that appear to be misbranded under section 502(f)(1) of the FD&C Act. While not specific to doxorubicin, this alert emphasizes the importance of compliance with labeling requirements for APIs intended for the U.S. market.

In April 2019, the EMA recommended the withdrawal of the marketing authorization for Lartruvo (olaratumab) in combination with doxorubicin, as the ANNOUNCE study concluded that the combination did not prolong the lives of patients with soft tissue sarcoma more than doxorubicin alone. This decision underscores the necessity of robust clinical evidence for combination therapies.

In September 2025, the marketing authorization for Celdoxome pegylated liposomal (doxorubicin) ceased to be valid in the EU, as the product had not been marketed within three years of its initial authorization. This highlights the importance of timely market entry following regulatory approval.

In March 2020, Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorization of Doxorubicin Hydrochloride Tillomed, intended for the treatment of various cancers. The withdrawal was due to the company's inability to address the CHMP's major objections within the available timeframe. This reflects the challenges companies may face in meeting stringent regulatory requirements.

These developments illustrate the dynamic regulatory landscape surrounding doxorubicin, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with approximately 80% of API requirements sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China. For instance, environmental regulations in China have previously led to the shutdown of chemical manufacturing units, causing supply shortages and price volatility for Indian pharmaceutical companies.

To mitigate these risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to bolster domestic API and KSM manufacturing. This initiative seeks to reduce reliance on imports by incentivizing local production through financial support and policy reforms. (pharmanow.live) However, the full impact of the PLI scheme on reducing import dependency is yet to be realized, as establishing new manufacturing capacities and achieving self-sufficiency in API production is a long-term endeavor.

The export market for Doxorubicin from India is highly concentrated, with the top five exporters accounting for 77.9% of total exports. SUN PHARMACEUTICAL INDUSTRIES LIMITED alone holds a 52.2% share, indicating a significant single-source risk. Such concentration can lead to supply disruptions if any of these key suppliers face operational challenges, regulatory issues, or other unforeseen events.

The PLI scheme, introduced to enhance domestic API production, aims to diversify the supplier base and reduce dependency on a few major players. By encouraging new entrants and supporting existing manufacturers to expand their capacities, the scheme seeks to create a more resilient supply chain. (pharmanow.live) However, the effectiveness of this initiative in mitigating supplier concentration risks will depend on its successful implementation and the industry's response to these incentives.

Recent geopolitical events have significantly impacted global supply chains. The closure of the Strait of Hormuz in February 2026, following military conflicts involving Iran, has disrupted the movement of oil and other critical commodities, including pharmaceuticals. This blockade has led to increased shipping costs, delays, and potential shortages of essential drugs.

Additionally, tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, forcing vessels to take longer, more expensive paths. These disruptions have a cascading effect on the pharmaceutical supply chain, leading to increased costs and potential delays in the delivery of medications.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers, both domestically and internationally, to reduce dependency on a single country or supplier.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme to boost local production capacities for APIs and KSMs, thereby enhancing supply chain resilience.

• Enhance Supplier Due Diligence: Conduct comprehensive assessments of suppliers' financial health, compliance records, and operational capabilities to identify and mitigate potential risks.

• Develop Contingency Plans: Establish robust contingency strategies, including maintaining strategic stockpiles and identifying alternative logistics routes, to address potential supply chain disruptions.

• Monitor Geopolitical Developments: Implement a proactive monitoring system to stay informed about geopolitical events that could impact supply chains, enabling timely responses to emerging threats.

RISK_LEVEL: HIGH